Ludwig Presence at 2018 ASCO Annual Meeting June 1 5, 2018

Size: px

Start display at page:

Download "Ludwig Presence at 2018 ASCO Annual Meeting June 1 5, 2018"

Teresa Holland
5 years ago
Views:

Ludwig Presence at 2018 ASCO Annual Meeting June 1 5, 2018 Ludwig Scientist Affiliation (s) Time Location Type Track Presentation/Abstract Title Saturday, June 2 Stephen Hodi Ludwig Harvard

1 Ludwig Presence at 2018 ASCO Annual Meeting June 1 5, 2018 Ludwig Scientist Affiliation (s) Time Location Type Track Presentation/Abstract Title Saturday, June 2 Stephen Hodi Ludwig Harvard 8:00-11:30 AM Hall A, Poster Board: #419a Poster Genitourinary (Nonprostate) Cancer Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. George Demetri Ludwig Harvard 8:00 11:30 AM Hall A, Poster Board: #255 Poster Sarcoma George Demetri Ludwig Harvard 8:00 11:30 AM Hall A, Poster Board: #258 Poster Sarcoma Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST) Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D) George Demetri Ludwig Harvard 8:00 11:30 AM Hall A, Poster Board: #296 Poster Sarcoma Targeted tumor profiling and actionable somatic variants in sarcoma Rakesh Jain Ludwig Harvard 8:00 11:30 AM Hall A, Poster Board: #107 Poster Breast Cancer Metastatic A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM). **scientist is senior author 1

2 Yang Liu Ludwig Laussane 8:00 11:30 AM Hall A, Poster Board: #271 Poster Sarcoma Comprehensive genomic profiling of sarcomas in Chinese population. Matt Van De Rijn Ludwig Stanford 8:00 11:30 AM Hall A, Poster Board: #288 Poster Sarcoma CDKN2A deletion as a prognostic marker: A clinicogenomic analysis of sarcoma patients Maximilian Diehn Ludwig Stanford 8:00 9:15 AM S406 Education Therapeutics and Translational Research Liquid Biopsies: Current Uses and Future Directions - Methods and Applications of cfdna Analysis Sushama Varma Ludwig Stanford 8:00 11:30 AM Hall A, Poster Board: #308 Poster Sarcoma Discovery and characterization of novel, recurrent, targetable ALK fusions in leiomyosarcoma Ralph Weichselbaum Ludwig Chicago 9:30 AM - 12:00 PM Hall B1 Opening Special s Opening With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture Sandro Santagata Ludwig Harvard 1:15-2:30 PM S100bc Education Central Nervous System Tumors Clinical Trials Therapeutics and Translational Research Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice Jedd Wolchok Ludwig MSK 1:15-2:30 PM S100a Education Special s ASCO/Radiological Society of North America (RSNA) Joint : Assessing Response and Progression With Targeted Thera and Immunothera - Immune-Related Response and RECIST in Radiographic Imaging Stephen Hodi Ludwig Harvard 1:15-4:45 PM Hall A, Poster Board: #169 Poster Central Nervous System Tumors Risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort **scientist is senior author 2

3 Joshua Cohen Ludwig John Hopkins 1:15-4:45 PM Hall A, Poster Board #61 Poster Head and Neck Cancer Cisplatin (CIS) versus cetuximab (CET) with definitive concurrent radiothera (RT) for head and neck squamous cell carcinoma (HNSCC): An analysis of veteran s health data. Joshua Cohen Ludwig John Hopkins 1:15-4:45 PM Hall A, Poster Board #338 Poster Health Services Research, Clinical Informatics, and Quality of Care Are National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) Affordability Ratings (AR) representative of real-world costs? An evaluation of advanced non small cell lung cancer (ansclc). Margaret Callahan** Ludwig MSK 3:00-6:00 PM Hall B1 Oral Abstract ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX /- nivolumab (nivo) in patients (pts) with advanced cancers. Margaret Callahan Ludwig MSK 3:00-6:00 PM Hall B1 Oral Abstract Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results. Ravindra Majeti, Irving L. Weissman Ludwig Stanford 3:00-6:00 PM Hall B1 Oral Abstract A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-cd47 monoclonal antibody (mab), in patients with advanced solid tumors. Stephen Hodi Ludwig Harvard 1:15-4:45 PM E451, Poster Board #169 Central Nervous System Tumors Risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort Sunday, June 3 Rakesh Jain Ludwig Harvard 8:00 11:30 AM Hall A, Poster Board #305 Poster Gastrointestinal Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study. **scientist is senior author 3

4 Joshua Cohen, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein Ludwig John Hopkins 8:00 11:30 AM Hall A, Poster Board #9 Poster Gastrointestinal (Colorectal) Cancer Serial circulating tumor DNA (ctdna) analysis as a prognostic marker and a real-time indicator of adjuvant chemothera (CT) efficacy in stage III colon cancer (CC). Yang Liu Ludwig Laussane 8:00-11:30 AM Hall A, Poster Board #241 Poster Gastrointestinal Comparison of clinical outcome and safety after minimally invasive esophagectomy: Ivor Lewis versus McKeown A real-world multicenter observational study from China. Taha Merghoub Ludwig MSK 8:00 11:30 AM Hall A, Poster Board #327b Poster Gastrointestinal A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-tace) in patients (pts) with liver limited hepatocellular carcinoma (HCC). Kristen Aufiero Ramirez, Paul Schwarzenberger, Toni Ricciardi, Aileen Ryan, Ralph Venhaus** Ludwig New York 8:00 11:30 AM Hall A, Poster Board: #428b Poster Lung Cancer Non-Small Cell Metastatic Phase 1/2 study of mrna vaccine thera + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC). Joshua Cohen, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein Ludwig John Hopkins 11:30 AM 12:45 PM Hall D2, Poster Board #9 Gastrointestinal (Colorectal) Cancer Serial circulating tumor DNA (ctdna) analysis as a prognostic marker and a real-time indicator of adjuvant chemothera (CT) efficacy in stage III colon cancer (CC). Monday, June 4 Stephen Hodi Ludwig Harvard 8:00-11:30 AM Hall A, Poster Board: #250 Poster Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors. Benjamin Izar*, Stephen Hodi Ludwig Harvard 8:00-11:30 AM Hall A, Poster Board: #288 Poster Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade. **scientist is senior author 4

5 Stephen Hodi Ludwig Harvard 8:00-11:30 AM Hall A, Poster Board: #228 Poster Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors. Stephen Hodi Ludwig Harvard 8:00-11:30 AM Hall A, Poster Board: #315a Poster Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination immuno-oncology (IO) therapies (ADVISE), a precision IO approach to personalized medicine Bianca Santomasso, Margaret Callahan** Ludwig MSK 8:00-11:30 AM Hall A, Poster Board: #298 Poster Neurologic immune related adverse events (iraes) in patients treated with immune checkpoint blockade. Michael Postow** Ludwig MSK 8:00-11:30 AM Hall A, Poster Board: #309 Poster Michael Postow, Jedd Wolchok** Ludwig MSK 8:00-11:30 AM Hall A, Poster Board: #227 Poster Pharmacodynamic and clinical activity of RGX-104, a firstin-class immunothera targeting the liver-x nuclear hormone receptor (LXR), in patients with refractory malignancies. Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. Matt Van De Rijn, Maximilian Diehn, Ash Alizadeh Ludwig Stanford 8:00 11:30 AM Hall A, Poster Board: #209 Poster Hematologic Malignancies Lymphoma and Chronic Lymphocytic Leukemia Early detection of post-transplant lymphoproliferative disorder using circulating tumor DNA. Stephen Hodi Ludwig Harvard 11:30-12:45 AM Hall B1, Poster Board: #228 Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors. Michael Postow, Jedd Wolchok** Ludwig MSK 11:30-12:45 AM Hall B1, Poster Board: #227 Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. **scientist is senior author 5

6 Ralph Weichselbaum Ludwig Chicago 1:15 4:45 PM Hall A, Poster Board: #252 Poster Gynecologic Cancer Benjamin Izar Ludwig Harvard 1:15 4:45 PM Hall A, Poster Board: #386 Poster Melanoma/Skin Cancers Benjamin Izar Ludwig Harvard 1:15 4:45 PM Hall A, Poster Board: #408 Poster Melanoma/Skin Cancers A phase 1/2A trial of synthetic DNA vaccine immunothera targeting HPV-16 and -18 after chemoradiation for cervical cancer. Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): Implications for combination with immunothera. Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunothera resistance Stephen Hodi, Jedd Wolchok Ludwig Harvard 1:15 4:45 PM Hall A, Poster Board: #343 Poster Melanoma/Skin Cancers 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001 Margaret Callahan, Michael Postow, Jedd Wolchok** Ludwig MSK 1:15 4:45 PM Hall A, Poster Board: #388 Poster Melanoma/Skin Cancers Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination thera in patients with cutaneous and unknown primary melanoma. Stephane Pourpe, Hyejin Choi, Taha Merghoub, Jedd Wolchok** Ludwig MSK 1:15 4:45 PM Hall A, Poster Board: #173 Poster Immunobiology Exploring effects of MEK inhibition in tumor microenvironment in non-small cell lung cancer (NSCLC) pre-clinical models. Teresa Rasalan, Dmitriy Zamarin, Phillip Wong Ludwig MSK 1:15 4:45 PM Hall A, Poster Board: #280 Poster Gynecologic Cancer A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission. Dmitriy Zamarin Ludwig MSK 1:15 4:45 PM Hall A, Poster Board: #258 Poster Gynecologic Cancer The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer. **scientist is senior author 6

7 Jedd Wolchok, Michael Postow** Ludwig MSK 1:15 4:45 PM Hall A, Poster Board: #379 Poster Melanoma/Skin Cancers Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma. Michael Postow*, Danielle McCabe, Paul Schwarzenberger, Toni Ricciardi, Aileen Ryan, Ralph Venhaus Ludwig MSK; Ludwig New York 1:15 4:45 PM Hall A, Poster Board: #377 Poster Melanoma/Skin Cancers Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) + ipilimumab (ipi) + external beam radiothera (RT) in patients with metastatic melanoma. Anthony Letai Ludwig Harvard 4:30 6:00 PM E450 Clinical Science Symposium Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML). Stephen Hodi, Jedd Wolchok Ludwig Harvard 1:15 4:45 PM E451, Poster Board #343 Melanoma/Skin Cancers 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001 Publication-only Abstracts Muriel Laine*, Marianne Greene, Ya- Fang Chang, Geoffrey Greene** Ludwig Chicago N/A N/A Publication-only abstracts Breast Cancer Metastatic Lasofoxifene efficacy in a mammary intraductal (MIND) xenograft model of ERα+ breast cancer. Rakesh Jain Ludwig Harvard N/A N/A Publication-only abstracts Gastrointestinal Angiotensin system inhibitors during induction chemothera for esophageal adenocarcinoma: Analysis of survival. Joshua Cohen Ludwig John Hopkins N/A N/A Publication-only abstracts Healthy Services Research, Clinical Informatics, and Quality of Care Cost-effectiveness of adjuvant chemothera in early stage breast cancer. **scientist is senior author 7

8 Joshua Cohen, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein Ludwig John Hopkins N/A N/A Publication-only abstracts Gastrointestinal Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer. Yang Liu Ludwig Laussane N/A N/A Publication-only abstracts Lung Cancer Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers A real-world observational study to explore clinical characteristics of Chinese patients with T1 non-small cell lung cancer complicated with lymph metastases. Yang Liu Ludwig Laussane N/A N/A Publication-only abstracts Lung Cancer Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Surgical treatments of Chinese patients with lung malignant tumors. Matthew Vander Heiden Ludwig MIT N/A N/A Publication-only abstracts Gastrointestinal Association between changing body composition after diagnosis and survival of patients with advanced pancreatic cancer. Michael Postow*, Jedd Wolchok Ludwig MSK N/A N/A Publication-only abstracts Tumor Biology Imaging of tumor infiltrating T cells with an anti-cd8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors. Michael Postow, Margaret Callahan, Jedd Wolchok Ludwig MSK N/A N/A Publication-only abstracts Melanoma/Skin Cancers Multigene sequencing, co number alteration detection, and survival with first-line PD-1 based thera in patients with mucosal melanoma. Jedd Wolchok, Margaret Callahan Ludwig MSK N/A N/A Publication-only abstracts Safety of influenza vaccination in patients undergoing immunothera treatment for advanced cancer. Margaret Callahan Ludwig MSK N/A N/A Publication-only abstracts Patient and Survivor Care Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors. **scientist is senior author 8

9 Michael Postow, Margaret Callahan, Jedd Wolchok Ludwig MSK N/A N/A Publication-only abstracts Melanoma/Skin Cancers Multigene sequencing, co number alteration detection, and survival with first-line PD-1 based thera in patients with mucosal melanoma. Kanika Arora, Taha Merghoub Ludwig MSK N/A N/A Publication-only abstracts Melanoma/Skin Cancers Clonal evolution of uveal melanoma metastases. Danny Khalil Ludwig MSK N/A N/A Publication-only abstracts Healthy Services Research, Clinical Informatics, and Quality of Care Total parenteral nutrition utilization in metastatic cancer patients: A nationwide 10-year analysis from 2006 to Michael Postow, Mary Macri, Ralph Venhaus, Jedd Wolchok Ludwig MSK; Ludwig New York N/A N/A Publication-only abstracts Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma. **scientist is senior author 9

Ludwig Presence at 2016 ASCO Annual Meeting

Ludwig Presence at 2016 ASCO Annual Meeting Ludwig Scientist(s) Affiliation(s) Session and Presentation Time Location Track Session Type/Title Presentation and/or Abstract Title Friday, June 3, 2016 Luisa Lina Villa Ludwig Sao Paulo 1:00pm - 3:15pm